Study of Cost-Consequences Analysis Between Salbutamol With Aminophyllin For Exacerbation Asthma

  • Amelia Lorensia Fakultas Farmasi, Universitas Surabaya
DOI: https://doi.org/10.24123/kesdok.V1i2.2855
Abstract Views: 1198 times
PDF Downloads: 1035 times
Keywords: cost-effectiveness analysis, asthma exacerbations, salbutamol, aminophylline

Abstract

Abstract— Exacerbations asthma treatment can be done by giving medications therapy in the form of salbutamol and aminophyllin. This research conducted with a comparative study between two alternatives using a hospital perspective. Data were collected retrospectively based on the medical records of patients with mild-moderate exacerbations asthma who were admitted in emergency department Anwar Medika Sidoarjo Hospital during the period of January 2017 to Desember 2018. The data showing asthma exacerbations treatment effectiveness and costs were analyzed using ACER. Results of the data analysis using ACER based on total improvement of asthma sympthoms showed that in salbutamol group was Rp.2.403,75/%, and in aminophyllin group was Rp.1.688,31/%. Based on the result of study, cannot concluded which medications therapy were more cost-effective because total subject study of salbutamol and aminophyllin were different and too little. Results of the data analysis using ACER based on total improvement of asthma sympthoms showed that in salbutamol only group was Rp.2.073,18/%, and in salbutamol and corticosteroid group was Rp.1.688,31/%. Rp.2.573,40/%. Based on the result of ACER, salbutamol only group more cost-effective than salbutamol and corticosteroid group based on improvement of asthma sympthoms in mild-moderate exacerbations asthma patients in emergency department.

Keywords: cost-effectiveness analysis, asthma exacerbations, salbutamol, aminophylline

Abstrak— Pengobatan serangan asma dapat dilakukan dengan cara pemberian terapi pengobatan, yaitu salbutamol dan aminofilin. Penelitian ini merupakan penelitian yang dilakukan dengan studi perbandingan antara dua alternatif yang ada dengan menggunakan perspektif rumah sakit. Pengumpulan data dilakukan secara retrospektif berdasarkan basis data rekam medik pasien serangan asma mild moderate yang di IGD di Rumah Sakit Umum Anwar Medika Sidoarjo periode Januari 2017 sampai dengan Desember 2018. Data efektivitas dan biaya pengobatan serangan asma dianalisis dengan ACER. Dari hasil analisis data diperoleh nilai ACER berdasarkan total perbaikan gejala pada kelompok salbutamol sebesar Rp.2.403,75/%, dan kelompok aminofilin sebesar Rp.1.688,31/%. Berdasarkan hasil penelitian, tidak dapat disimpulkan terapi pengobatan yang lebih cost-effective karena jumlah subjek kelompok salbutamol dan kelompok aminofilin yang berbeda dan terlalu sedikit. Dari hasil analisis data diperoleh nilai ACER berdasarkan total perbaikan gejala pada penggunaan salbutamol tunggal sebesar Rp.2.073,18/%, pada kelompok salbutamol dan kortikosteroid sebesar Rp.2.573,40/%. Berdasarkan hasil nilai ACER tersebut, kelompok salbutamol tunggal lebih cost-effective dibandingkan kelompok salbutamol dan kortikosteroid berdasarkan perbaikan gejala pada pasien serangan asma mild moderate di IGD.

Kata kunci: analisis efektivitas biaya, serangan asma, salbutamol, aminofilin

Downloads

Download data is not yet available.

References

  1. Network GA. The Global Asthma Report 2014 [Internet]. 2014. Available from: http://globalasthmareport.org/burden/burden.php


  2. Riskesdas. Hasil Utama Riset Kesehatan Dasar Tahun 2018. Kementrian Kesehat Republik Indones. 2018;1–100.


  3. Initiative G. Global Initiative for Asthma: Global strategy for asthma management and prevention (Updated 2020). Rev Fr d’Allergologie d’Immunologie Clin [Internet]. 2020;36(6):685–704. Available from: https://ginasthma.org/wp-content/uploads/2020/04/GINA-2020-full-report_-final-_wms.pdf


  4. Lorensia A, Farmakoekonomi: Menghadapi Tingginya Lonjakan Biaya Pengobatan yang Mengancam Kestabilan Perekonomian. 2018. Surabaya: M-Brothers Indonesia.


  5. Institute for Transportation (Durham NC., Advanced Transit Association (Washington DC. Journal of advanced transportation. J Adv Transp [Internet]. 2018;(1):1–19. Available from: http://search.ebscohost.com/login.aspx?direct=true&db=a9h&AN=128298700&site=eds-live


  6. Lorensia A, Wahjuningsih E. Keamanan Penggunaan Aminofilin pada Pengobatan Asma di Rumah Sakit Delta Surya Sidoarjo Safety of Aminophylline for Asthma Therapy in Delta Surya Hospital at Sidoarjo. J Farm Klin Indones. 2012;1(4):154–61.


  7. L Lorensia A, Canggih B, Wijaya RI. Analisa Adverse Drug Reactions pada Pasien Asma di Suatu Rumah Sakit, Surabaya. Jurnal Farmasi Indonesia. 2013;6(3):142―50.


  8. Lorensia A, Amalia R. Studi Farmakovigilans Pengobatan Asma Pada Pasien Rawat Inap Di Suatu Rumah Sakit Di Bojonegoro. J Ilm Manuntung. 2015;1(1):8–18.


  9. Lorensia A, Ikawati Z, Andayani TM, Maranatha D, Suryadinata RV, Hantoro KAA, Firanita LD. Efektivitas dan Risiko Toksisitas Aminofilin Intravena pada Pengobatan Awal Serangan Asma. Jurnal Farmasi Klinik Indonesia. 2018;7(2):78―88.


  10. Lorensia A, Ikawati Z, Andayani TM, Maranatha D, Amalia R. Membandingkan Kejadian Gangguan Gastrointestinal Penggunaan Aminofilin dan Salbutamol pada Pasien Eksaserbasi Asma di Surabaya. KELUWIH J Kesehat dan Kedokt. 2019;1(1):1.


  11. Queljoe DD, Wahjudi M, Erdiansyah M, Suryadinata RV, Lorensia A. Pilot Study on Genetic Polymorphisms CYP1A2*1F on Asthma Patients and Nonasthma in Indonesia. Indones J Clin Pharm. 2015;4(1):8–16.


  12. Lorensia A, Ikawati Z, Andayani TM, Maranatha D, Wahjudi M. Cost-Effectiveness Analysis of Intravenous Aminophylline Versus Nebulized Salbutamol in Length of Treatment of Exacerbation Asthma Patient in Emergency Care. ISPOR (International Society for Pharmacoeconomics and Outcomes Research) Indonesia. 2016.


  13. Al-Shamrani A, Al-Harbi AS, Bagais K, Alenazi A, Alqwaiee M. Management of asthma exacerbation in the emergency departments. Int J Pediatr Adolesc Med. 2019;6(2):61–7.


  14. Alangari AA. Corticosteroids in the treatment of acute asthma. Ann Thorac Med. 2014;9(4):187–92.


  15. Gosden T, Pitcher A, Nour N, Madoni A, Friggi E. A Cost-Effectiveness Analysis of a First-in-Class, Triple Fixed Dose Combination Therapy Against Laba/Lama Therapy in Moderate-Severe COPD. Value Heal. 2018;21:S235.


  16. Ismaila AS, Risebrough N, Li C, Corriveau D, Hawkins N, Mark Fitzgerald J, et al. COST-effectiveness of salmeterol/fluticasone propionate combination (Advair®) in uncontrolled asthma in Canada. Respir Med [Internet]. 2014;108(9):1292–302.


Published
2020-06-26
How to Cite
Lorensia, A. (2020). Study of Cost-Consequences Analysis Between Salbutamol With Aminophyllin For Exacerbation Asthma. Keluwih: Jurnal Kesehatan Dan Kedokteran, 1(2), 60-66. https://doi.org/10.24123/kesdok.V1i2.2855
Issue
Vol. 1 No. 2 (2020): Keluwih: Jurnal Kesehatan dan Kedokteran (June)
Section
Original Research
Copyright (c) 2020 Amelia Lorensia Creative Commons License

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

  • Articles published in Keluwih: JKK are licensed under a Creative Commons Attribution-ShareAlike 4.0 International license. You are free to copy, transform, or redistribute articles for any lawful purpose in any medium, provided you give appropriate credit to the original author(s) and the journal, link to the license, indicate if changes were made, and redistribute any derivative work under the same license.
  • Copyright on articles is retained by the respective author(s), without restrictions. A non-exclusive license is granted to Kluwih: JKK to publish the article and identify itself as its original publisher, along with the commercial right to include the article in a hardcopy issue for sale to libraries and individuals.
  • By publishing in Keluwih: JKK, authors grant any third party the right to use their article to the extent provided by the Creative Commons Attribution-ShareAlike 4.0 International license.